Novo Nordisk and OpenAI forge major AI alliance to accelerate drug discovery & healthcare operations
The collaboration will embed OpenAI’s advanced AI systems across Novo Nordisk’s global operations
The collaboration will embed OpenAI’s advanced AI systems across Novo Nordisk’s global operations
The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
Strong limited rollout adoption across major hospital networks positions company for accelerated scale-up in interventional radiology
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
API-first, DPI-driven DDRS platform aims to modernize drug and medical device regulation in India
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
Move amid evidence of widespread reporting gaps
AI-enabled women’s digital clinic brings in-person consultations to complement app-led care after serving over 400,000 women across India
Subscribe To Our Newsletter & Stay Updated